SCHEMBL30765730

SCHEMBL30765730

C[C@@H](Nc1ncc(C2=CCOCC2)n(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 6/20 0.41
EGFR P00533 2/20 0.34
LMNA P02545 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
IKBKE Q14164 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
AURKA O14965 1/20 0.31
RPS6KB1 P23443 1/20 0.31
AADAT Q8N5Z0 1/20 0.31
GSK3B P49841 1/20 0.31
BRD4 O60885 1/20 0.31
TAF1 P21675 1/20 0.31
NPY5R Q15761 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765882 0.88 SOS1 (0.37) SOS1EGFRLMNA
SCHEMBL30765462 0.83 MAPK1 (0.35) SOS1HDAC6
SCHEMBL31558425 0.82 MEN1 (0.36) EGFRLMNAHDAC6AURKARPS6KB1
SCHEMBL30765748 0.81 SOS1 (0.40) SOS1EGFRLMNAAURKARPS6KB1
Potassium Ion SCHEMBL30765480 0.79 F7 (0.36) EGFRLMNAHDAC6
SCHEMBL30765943 0.78 SOS1 (0.41) SOS1EGFRBRD4TAF1
SCHEMBL31558541 0.74 SOS1 (0.39) SOS1EGFRLMNAAURKARPS6KB1
SCHEMBL30766075 0.74 HDAC6 (0.42) SOS1LMNAHDAC6NPY5R
SCHEMBL30765619 0.74 LMNA (0.38) LMNAHDAC6NPY5R
SCHEMBL31558435 0.73 ELANE (0.45) LMNAHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed